DOTAconjugation DOTA peptides represent a sophisticated class of molecules that are revolutionizing medical diagnostics and therapeutics, particularly in the field of oncology. These compounds combine the targeting capabilities of peptides with the strong metal-chelating properties of 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid (DOTA). This powerful conjugation allows for the precise delivery of radionuclides to specific biological targets, enabling highly effective imaging and treatment of various diseases, most notably neuroendocrine tumors and other cancers. The development and application of DOTA-peptides are central to advancements in personalized medicine, offering new avenues for disease detection, staging, and targeted therapy.Practical aspect in optimizing radiolabeling of DOTA-peptides ...
The core utility of DOTA peptides lies in their ability to form stable complexes with a wide range of medically relevant metal isotopesPractical Aspects of labeling DTPA- and DOTA- Peptides with. The DOTA molecule acts as a cage, securely binding to radionuclides such as Gallium-68 (⁶⁸Ga) for Positron Emission Tomography (PET) imaging, or Lutetium-177 (¹⁷⁷Lu) and Yttrium-90 (⁹⁰Y) for therapeutic applications in Peptide Receptor Radionuclide Therapy (PRRT).DOTATATE acetate | DOTA-Conjugated Peptide This precise radiolabeling is crucial for both diagnostic accuracy and therapeutic efficacy, ensuring that the radionuclide is delivered directly to the intended site with minimal off-target exposure...peptides(37)(38)(39). TheDOTAmonoamide conjugatedpeptide[Tyr 3 ]-octreotide (DOTA-TOC) (Fig. 6) showed very promising in vivo and in vitro properties ....
DOTA, a macrocyclic chelator, is exceptionally adept at forming highly stable complexes with metal ions. Its structure provides multiple coordination sites, which are essential for encapsulating radionuclides securely. When coupled with specific peptides, DOTA acts as a bifunctional linker, allowing the peptide to bind to its target receptor while the DOTA moiety carries the radionuclide. This strategic pairing is fundamental to the development of agents like DOTATATE and DOTATOC, which target somatostatin receptors often overexpressed on neuroendocrine tumorsDOTATATE | DOTA-Conjugated Peptide - MedchemExpress.com.
The synthesis of DOTA-peptide conjugates involves intricate chemical processes. Solid-phase synthesis is a common methodology that allows for the controlled and versatile introduction of DOTA into peptide sequences. This approach facilitates the creation of custom DOTA-peptides tailored for specific diagnostic or therapeutic purposes. Researchers continuously refine these labeling procedures of DOTA-peptides to optimize reaction kinetics, yield, and the purity of the final radiolabeled productDOTA-JR11 is a somatostatin receptor 2 （SSTR2）antagonist.DOTA-JR11 can be labeled by 68Ga, used for paired imaging in neuroendocrine tumors (NETs) research.. Ensuring high radiochemical purity and specific activity is paramount for reliable clinical outcomes.
In diagnostic imaging, DOTA peptides are primarily used with positron-emitting radionuclides like ⁶⁸Ga. The resulting ⁶⁸Ga-labeled DOTA-peptides are invaluable for PET imaging, offering high sensitivity and resolution for visualizing receptor-mediated processesDOTATATE | DOTA-Conjugated Peptide - MedchemExpress.com. A prominent example is their use in imaging neuroendocrine tumors (NETs). By targeting somatostatin receptors, these radiotracers enable the visualization and quantification of receptor expression across the body, providing critical insights into tumor biology, receptor status, and guiding treatment decisions. The ability to perform PET/CT with 68Gallium-DOTA-peptides has significantly improved the detection and management of NETs, allowing for more precise staging and monitoring of treatment responsePeptide Conjugates.
Beyond NETs, research is exploring the potential of DOTA-peptides for imaging other cancer types, such as neuroblastomaDOTATATE acetate is a DOTA-conjugated peptide. DOTATATE acetate can be labelled with radionuclides for positron emission tomography (PET) imaging.. The development of novel DOTA-peptide conjugates targeting different receptors is an ongoing area of research, aiming to expand the diagnostic utility of this technology.
The therapeutic potential of DOTA peptides is realized through Peptide Receptor Radionuclide Therapy (PRRT). In this approach, DOTA-peptides are labeled with therapeutic beta-emitting or alpha-emitting radionuclides, such as ¹⁷⁷Lu or ⁹⁰Y. These radiolabeled peptides then bind to target receptors on cancer cells, delivering a cytotoxic radiation dose directly to the tumor.
¹⁷⁷Lu-DOTATATE, for instance, has emerged as a significant treatment option for patients with unresectable or metastatic gastroenteropancreatic neuroendocrine tumors. This therapy leverages the high avidity of somatostatin receptors on these tumors to deliver targeted radiation, leading to tumor regression and improved patient survival.DOTA-TATE The stability of the DOTA chelate is crucial here, ensuring that the therapeutic radionuclide remains bound to the peptide throughout its journey to the tumor and during its therapeutic action作者：LM De León‐Rodriguez·2004·被引用次数：91—A general synthetic route to twoDOTA-linked N-Fmoc amino acids (DOTA-F andDOTA-K) is described that allows insertion ofDOTAat any endo-position within a ....
The efficacy of PRRT also depends on optimizing labeling procedures of DOTA-peptides and ensuring consistent quality control. Factors such as the specific activity, incorporation yield, and radiochemical purity of the final labeled peptides are rigorously assessed to guarantee the safety and effectiveness of the treatment....peptides(37)(38)(39). TheDOTAmonoamide conjugatedpeptide[Tyr 3 ]-octreotide (DOTA-TOC) (Fig. 6) showed very promising in vivo and in vitro properties ...
Despite the significant progress, challenges remain in the field of DOTA peptidesDOTATATE (Oxodotreotide) is an octreotate-based peptide featuring a tyrosine substitution at position 3 and a DOTA chelator for radiolabeling.. Optimizing synthesis and labeling protocols for various radionuclides and peptide sequences is an ongoing endeavor. Furthermore, understanding the pharmacokinetics and dosimetry of these agents is crucial for personalized treatment planning作者：WAP Breeman·被引用次数：2—Discuss the stability, specific activity, incorporation yield, and radiochemical purity of thefinal labeled DTPA- and DOTA-conjugated peptides.. Research is also focused on developing new DOTA-peptide conjugates with improved targeting specificity and therapeutic indices for a broader range of cancers. The exploration of alpha-emitters with DOTA conjugates also holds promise for more potent targeted therapies. As the field evolves, DOTA peptides are poised to play an even more significant role in precision medicine, offering advanced diagnostic and therapeutic solutions作者：JK Sosabowski·2006·被引用次数：101—Thepeptideis first conjugated to a chelating agent that is able to form stable complexes with the radionuclide of interest..
Join the newsletter to receive news, updates, new products and freebies in your inbox.